SCHEMBL4919214

SCHEMBL4919214

COC(=O)c1[c][nH]c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.50
CREBBP Q92793 1/20 0.50
KDM4E B2RXH2 6/20 0.49
STAT3 P40763 1/20 0.49
HIF1A Q16665 1/20 0.49
KIF11 P52732 1/20 0.46
IDO1 P14902 1/20 0.46
PTPN1 P18031 1/20 0.46
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.42
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289937 0.82 GABRA1 (0.46) NR4A2CREBBPKDM4ESTAT3HIF1A
SCHEMBL4919209 0.82 KDM4E (0.52) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL5473200 0.80 PBRM1 (0.46) NR4A2CREBBPKDM4EALDH1A1MEN1
SCHEMBL9587428 0.79 YTHDC1 (0.49) NR4A2CREBBPKDM4EALDH1A1HPGD
SCHEMBL1642680 0.78 KDM4E (0.42) NR4A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10853951 0.78 NR4A2 (0.55) NR4A2HIF1AALDH1A1MEN1KMT2A
SCHEMBL1642667 0.77 ALDH1A1 (0.46) KDM4ESTAT3ALDH1A1HPGDHSD17B10
SCHEMBL29135561 0.76 GAA (0.45) KDM4ESTAT3ALDH1A1MEN1KMT2A
SCHEMBL16756178 0.75 CYP3A4 (0.51) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL201717 0.73 CCNA2 (0.51) KDM4EHIF1APTPN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PFIZER INC. 2008-08-21 US disclosed
EP-1866317-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-12-19 EP disclosed
WO-2006103555-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed
US-4611064-A Preparation of indole derivatives BASF AKTIENGESELLSCHAFT (DE) 1986-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PF4, TBXA2R, P2RY4 NR4A2 2249/4885CREBBP 4230/4885KDM4E 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.